Therapeutic approaches for neuronopathic lysosomal storage disorders

Journal of Inherited Metabolic Disease

Volumn 33, Issue 4, 2010, Pages 373-379

  Schiffmann, Raphael ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA MANNOSIDASE; ANTIINFLAMMATORY AGENT; APOLIPOPROTEIN B; ARYLSULFATASE; BETA GLUCURONIDASE; CHAPERONE; CYCLOSERINE; GLATIRAMER; GLUCOSYLCERAMIDASE; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; LENTIVIRUS VECTOR; LEVO IDURONIDASE; MIGLUSTAT; N OCTYL 4 EPI BETA VALIENAMINE; N4 (BETA N ACETYLGLUCOSAMINYL)ASPARAGINASE; PYRIMETHAMINE; TACROLIMUS; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ASPARTYLGLYCOAMINURIA; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM DISEASE; DRUG DELIVERY SYSTEM; DRUG MEGADOSE; ENZYME REPLACEMENT; ENZYME SUBSTRATE; GENE THERAPY; GLOBOID CELL LEUKODYSTROPHY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUNTER SYNDROME; HURLER SYNDROME; LYSOSOME STORAGE DISEASE; METACHROMATIC LEUKODYSTROPHY; NIEMANN PICK DISEASE; NONHUMAN; REVIEW; SANDHOFF DISEASE; SUBSTRATE REDUCTION THERAPY; LYSOSOMAL STORAGE DISEASES;

ANTI-INFLAMMATORY AGENTS; ENZYME REPLACEMENT THERAPY; GENE THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYSOSOMAL STORAGE DISEASES; GENETIC THERAPY;

EID: 77956061221     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-010-9047-0     Document Type: Review

References (81)

1. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ (2010) Structure and function of the blood-brain barrier. Neurobiol Dis 37: 13-25
2. ACOG Committee on Genetics (2009) ACOG Committee Opinion No. 442: Preconception and prenatal carrier screening for genetic diseases in individuals of Eastern European Jewish descent. Obstet Gynecol 114:950-953
3. A Abe S Gregory L Lee PD Killen RO Brady A Kulkarni JA Shayman 2000 Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation J Clin Invest 105 1563 1571 10.1172/JCI9711 1:CAS:528: DC%2BD3cXjvFWmtrk%3D 10841515
4. AR Alvarez A Klein J Castro GI Cancino J Amigo M Mosqueira LM Vargas LF Yevenes FC Bronfman S Zanlungo 2008 Imatinib therapy blocks cerebellar apoptosis and improves neurological symptoms in a mouse model of Niemann-Pick type C disease FASEB J 22 3617 3627 10.1096/fj.07-102715 1:CAS:528:DC%2BD1cXht1SqsrbF 18591368
5. DJ Begley CC Pontikis M Scarpa 2008 Lysosomal storage diseases and the blood-brain barrier Curr Pharm Des 14 1566 1580 10.2174/138161208784705504 1:CAS:528:DC%2BD1cXoslyksr4%3D 18673198
6. A Biffi M De Palma A Quattrini U Del Carro S Amadio I Visigalli M Sessa S Fasano R Brambilla S Marchesini C Bordignon L Naldini 2004 Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells J Clin Invest 113 1118 1129 1:CAS:528:DC%2BD2cXjt1yis7g%3D 15085191
7. S Biswas SM LeVine 2002 Substrate-reduction therapy enhances the benefits of bone marrow transplantation in young mice with globoid cell leukodystrophy Pediatr Res 51 40 47 10.1203/00006450-200201000-00009 11756638
8. J Blanz S Stroobants R Lullmann-Rauch W Morelle M Ludemann R D'Hooge H Reuterwall JC Michalski J Fogh C Andersson P Saftig 2008 Reversal of peripheral and central neural storage and ataxia after recombinant enzyme replacement therapy in alpha-mannosidosis mice Hum Mol Genet 17 3437 3445 10.1093/hmg/ddn237 1:CAS:528:DC%2BD1cXht12isb3N 18713755
9. RJ Boado Y Zhang CF Xia Y Wang WM Pardridge 2008 Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier Biotechnol Bioeng 99 475 484 10.1002/bit.21602 1:CAS:528:DC%2BD1cXnsVKktQ%3D%3D 17680664
10. RO Brady 2006 Enzyme replacement for lysosomal diseases Annu Rev Med 57 283 296 10.1146/annurev.med.57.110104.115650 1:CAS:528:DC%2BD28Xis1CksL0%3D 16409150
11. S Buechner M Moretti AP Burlina G Cei R Manara R Ricci R Mignani R Parini R Di Vito GP Giordano P Simonelli G Siciliano W Borsini 2008 Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective study J Neurol Neurosurg Psychiatry 79 1249 1254 10.1136/jnnp.2008.143693 1:STN:280:DC%2BD1cnnsFyltw%3D%3D 18535022
12. CN Cearley JH Wolfe 2007 A single injection of an adeno-associated virus vector into nuclei with divergent connections results in widespread vector distribution in the brain and global correction of a neurogenetic disease J Neurosci 27 9928 9940 10.1523/JNEUROSCI.2185-07.2007 1:CAS:528: DC%2BD2sXhtVyksbjI 17855607
13. Chen YH, Chang M, Davidson BL (2009) Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy. Nat Med 15:1215-1218
14. C Di Domenico GR Villani D Di Napoli E Nusco G Cali L Nitsch P Di Natale 2009 Intracranial gene delivery of LV-NAGLU vector corrects neuropathology in murine MPS IIIB Am J Med Genet 149A 1209 1218 10.1002/ajmg.a.32861 19449420
15. P Dickson M McEntee C Vogler S Le B Levy M Peinovich S Hanson M Passage E Kakkis 2007 Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid Mol Genet Metab 91 61 68 10.1016/j.ymgme.2006.12.012 1:CAS:528:DC%2BD2sXkt1ehurk%3D 17321776
16. U Dunder V Kaartinen P Valtonen E Vaananen VM Kosma N Heisterkamp J Groffen I Mononen 2000 Enzyme replacement therapy in a mouse model of aspartylglycosaminuria FASEB J 14 361 367 1:CAS:528:DC%2BD3cXisFKksr8%3D 10657992
17. E Elliot-Smith AO Speak E Lloyd-Evans DA Smith AC van der Spoel M Jeyakumar TD Butters RA Dwek A d'Azzo FM Platt 2008 Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis Mol Genet Metab 94 204 211 10.1016/j.ymgme.2008.02.005 1:CAS:528:DC%2BD1cXmtVSgtbg%3D 18387328
18. ML Escolar MD Poe JM Provenzale KC Richards J Allison S Wood DA Wenger D Pietryga D Wall M Champagne R Morse W Krivit J Kurtzberg 2005 Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease N Engl J Med 352 2069 2081 10.1056/NEJMoa042604 1:CAS:528:DC%2BD2MXkt1Kltrg%3D 15901860
19. JQ Fan S Ishii 2007 Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors FEBS J 274 4962 4971 10.1111/j.1742-4658.2007.06041.x 1:CAS:528:DC%2BD2sXhtFeksrfO 17894781
20. DR Fleming PJ Henslee-Downey G Ciocci EH Romond E Marciniak RK Munn JS Thompson 1998 The use of partially HLA-mismatched donors for allogeneic transplantation in patients with mucopolysaccharidosis-I Pediatr Transplant 2 299 304 1:STN:280:DyaK1M7ot1anuw%3D%3D 10084733
21. A Fraldi K Hemsley A Crawley A Lombardi A Lau L Sutherland A Auricchio A Ballabio JJ Hopwood 2007 Functional correction of CNS lesions in an MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes Hum Mol Genet 16 2693 2702 10.1093/hmg/ddm223 1:CAS:528:DC%2BD2sXht1aksbjE 17725987
22. JH Grubb C Vogler B Levy N Galvin Y Tan WS Sly 2008 Chemically modified beta-glucuronidase crosses blood-brain barrier and clears neuronal storage in murine mucopolysaccharidosis VII Proc Natl Acad Sci U S A 105 2616 2621 10.1073/pnas.0712147105 1:CAS:528:DC%2BD1cXis1Oqtb8%3D 18268347
23. JH Grubb C Vogler Y Tan GN Shah AF MacRae WS Sly 2008 Infused Fc-tagged beta-glucuronidase crosses the placenta and produces clearance of storage in utero in mucopolysaccharidosis VII mice Proc Natl Acad Sci U S A 105 8375 8380 10.1073/pnas.0803715105 1:CAS:528:DC%2BD1cXnvVKrsrw%3D 18544647
24. N Gungor E Tuncbilek 1995 Sanfilippo disease type B. A case report and review of the literature on recent advances in bone marrow transplantation Turk J Pediatr 37 157 163 1:STN:280:DyaK2MzitV2gtg%3D%3D 7597767
25. M Haskins 2009 Gene therapy for lysosomal storage diseases (LSDs) in large animal models ILAR J 50 112 121 1:CAS:528:DC%2BD1MXps1eksb8%3D 19293456
26. KM Hemsley B King JJ Hopwood 2007 Injection of recombinant human sulfamidase into the CSF via the cerebellomedullary cistern in MPS IIIA mice Mol Genet Metab 90 313 328 10.1016/j.ymgme.2006.10.005 1:CAS:528: DC%2BD2sXitFOqs7g%3D 17166757
27. Hemsley KM, Beard H, King BM, Hopwood JJ (2008) Effect of high dose, repeated intra-CSF injection of sulphamidase on neuropathology in MPS IIIA mice. Genes Brain Behav 7:740-753
28. KM Hemsley AJ Luck AC Crawley S Hassiotis H Beard B King T Rozek T Rozaklis M Fuller JJ Hopwood 2009 Examination of intravenous and intra-CSF protein delivery for treatment of neurological disease Eur J NeuroSci 29 1197 1214 10.1111/j.1460-9568.2009.06666.x 19302155
29. MJ Hilz M Brys H Marthol B Stemper M Dutsch 2004 Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy Neurology 62 1066 1072 1:CAS:528:DC%2BD2cXktFGjtLw%3D 15079003
30. M Jeyakumar TD Butters M Cortina-Borja V Hunnam RL Proia VH Perry RA Dwek FM Platt 1999 Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin Proc Natl Acad Sci U S A 96 6388 6393 10.1073/pnas.96.11.6388 1:CAS:528:DyaK1MXksFKkt7o%3D 10339597
31. M Jeyakumar F Norflus CJ Tifft M Cortina-Borja TD Butters RL Proia VH Perry RA Dwek FM Platt 2001 Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation Blood 97 327 329 10.1182/blood.V97.1.327 1:CAS:528:DC%2BD3MXis1Cgsw%3D%3D 11133779
32. M Jeyakumar R Thomas E Elliot-Smith DA Smith AC van der Spoel A d'Azzo VH Perry TD Butters RA Dwek FM Platt 2003 Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis Brain 126 974 987 10.1093/brain/awg089 1:STN:280:DC%2BD3s7gt1alsQ%3D%3D 12615653
33. M Jeyakumar DA Smith IM Williams MC Borja DC Neville TD Butters RA Dwek FM Platt 2004 NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin Ann Neurol 56 642 649 10.1002/ana.20242 1:CAS:528:DC%2BD2cXhtVCgsLjM 15505823
34. E Kakkis M McEntee C Vogler S Le B Levy P Belichenko W Mobley P Dickson S Hanson M Passage 2004 Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I Mol Genet Metab 83 163 174 10.1016/j.ymgme.2004.07.003 1:CAS:528:DC%2BD2cXotF2ntrk%3D 15464431
35. T Kurai S Hisayasu R Kitagawa M Migita H Suzuki Y Hirai T Shimada 2007 AAV1 mediated co-expression of formylglycine-generating enzyme and arylsulfatase A efficiently corrects sulfatide storage in a mouse model of metachromatic leukodystrophy Mol Ther 15 38 43 10.1038/sj.mt.6300012 1:CAS:528: DC%2BD2sXhtVejurjL 17164773
36. HD Lacorazza JD Flax EY Snyder M Jendoubi 1996 Expression of human beta-hexosaminidase alpha-subunit gene (the gene defect of Tay-Sachs disease) in mouse brains upon engraftment of transduced progenitor cells Nat Med 2 424 429 10.1038/nm0496-424 1:CAS:528:DyaK28XitVKmtrw%3D 8597952
37. C Laurie A Reynolds O Coskun E Bowman HE Gendelman RL Mosley 2007 CD4+ T cells from copolymer-1 immunized mice protect dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease J Neuroimmunol 183 60 68 10.1016/j.jneuroim.2006.11.009 1:CAS:528: DC%2BD2sXhs1Citbk%3D 17196666
38. WC Lee A Courtenay FJ Troendle ML Stallings-Mann CA Dickey MW DeLucia DW Dickson CB Eckman 2005 Enzyme replacement therapy results in substantial improvements in early clinical phenotype in a mouse model of globoid cell leukodystrophy FASEB J 19 1549 1551 10.1096/fj.04-2591hyp 1:CAS:528: DC%2BD2MXpvF2gtLw%3D 15987783
39. WC Lee YK Tsoi FJ Troendle MW DeLucia Z Ahmed CA Dicky DW Dickson CB Eckman 2007 Single-dose intracerebroventricular administration of galactocerebrosidase improves survival in a mouse model of globoid cell leukodystrophy FASEB J 21 2520 2527 10.1096/fj.06-6169com 1:CAS:528: DC%2BD2sXptFKhu74%3D 17403939
40. P Luzi MA Rafi M Zaka HZ Rao M Curtis MT Vanier DA Wenger 2005 Biochemical and pathological evaluation of long-lived mice with globoid cell leukodystrophy after bone marrow transplantation Mol Genet Metab 86 150 159 10.1016/j.ymgme.2005.06.023 1:CAS:528:DC%2BD2MXhtVOksLbM 16169269
41. GH Maegawa M Tropak J Buttner T Stockley F Kok JT Clarke DJ Mahuran 2007 Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis J Biol Chem 282 9150 9161 10.1074/jbc.M609304200 1:CAS:528:DC%2BD2sXivV2mtL4%3D 17237499
42. GH Maegawa BL Banwell S Blaser G Sorge M Toplak C Ackerley C Hawkins J Hayes JT Clarke 2009 Substrate reduction therapy in juvenile GM2 gangliosidosis Mol Genet Metab 98 215 224 10.1016/j.ymgme.2009.06.005 1:CAS:528: DC%2BD1MXptlWku7k%3D 19595619
43. D Malm O Nilssen 2008 Alpha-mannosidosis Orphanet J Rare Dis 3 21 10.1186/1750-1172-3-21 18651971
44. G Malm B Gustafsson G Berglund M Lindstrom K Naess B Borgstrom U von Dobeln O Ringden 2008 Outcome in six children with mucopolysaccharidosis type IH, Hurler syndrome, after haematopoietic stem cell transplantation (HSCT) Acta Paediatr 97 1108 1112 10.1111/j.1651-2227.2008.00811.x 18452566
45. U Matzner E Herbst KK Hedayati R Lullmann-Rauch C Wessig S Schroder C Eistrup C Moller J Fogh V Gieselmann 2005 Enzyme replacement improves nervous system pathology and function in a mouse model for metachromatic leukodystrophy Hum Mol Genet 14 1139 1152 10.1093/hmg/ddi126 1:CAS:528:DC%2BD2MXjvFamur8%3D 15772092
46. AM Montano H Oikawa S Tomatsu T Nishioka C Vogler MA Gutierrez T Oguma Y Tan JH Grubb VC Dung A Ohashi K Miyamoto T Orii Y Yoneda WS Sly 2008 Acidic amino acid tag enhances response to enzyme replacement in mucopolysaccharidosis type VII mice Mol Genet Metab 94 178 189 10.1016/j.ymgme.2008.01.007 1:CAS:528:DC%2BD1cXmtVSgtbo%3D 18359257
47. MV Munoz-Rojas T Vieira R Costa S Fagondes A John LB Jardim LM Vedolin M Raymundo PI Dickson E Kakkis R Giugliani 2008 Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression Am J Med Genet 146A 2538 2544 10.1002/ajmg.a.32294 18792977
48. T Okuda K Furukawa K Nakayama 2009 A novel, promoter-based, target-specific assay identifies 2-deoxy-D-glucose as an inhibitor of globotriaosylceramide biosynthesis FEBS J 276 5191 5202 10.1111/j.1742-4658. 2009.07215.x 1:CAS:528:DC%2BD1MXhtFChtrnJ 19674101
49. PJ Orchard BR Blazar J Wagner L Charnas W Krivit J Tolar 2007 Hematopoietic cell therapy for metabolic disease J Pediatr 151 340 346 10.1016/j.jpeds.2007.04.054 17889065
50. MA Passini J Bu JA Fidler RJ Ziegler JW Foley JC Dodge WW Yang J Clarke TV Taksir DA Griffiths MA Zhao CR O'Riordan EH Schuchman LS Shihabuddin SH Cheng 2007 Combination brain and systemic injections of AAV provide maximal functional and survival benefits in the Niemann-Pick mouse Proc Natl Acad Sci U S A 104 9505 9510 10.1073/pnas.0703509104 1:CAS:528:DC%2BD2sXmtlGru74%3D 17517638
51. GM Pastores NL Barnett EH Kolodny 2005 An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment Clin Ther 27 1215 1227 10.1016/j.clinthera.2005.08.004 1:CAS:528:DC%2BD2MXhtFWgurfM 16199246
52. MC Patterson D Vecchio H Prady L Abel JE Wraith 2007 Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study Lancet Neurol 6 765 772 10.1016/S1474-4422(07)70194-1 1:CAS:528:DC%2BD2sXhtVyrsr3F 17689147
53. 2+-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-butyldeoxynojirimycin J Biol Chem 278 29496 29501 10.1074/jbc.M302964200 1:CAS:528:DC%2BD3sXlvFOgurY%3D 12756243
54. D Pelled S Trajkovic-Bodennec E Lloyd-Evans E Sidransky R Schiffmann AH Futerman 2005 Enhanced calcium release in the acute neuronopathic form of Gaucher disease Neurobiol Dis 18 83 88 10.1016/j.nbd.2004.09.004 1:CAS:528:DC%2BD2MXkslOhug%3D%3D 15649698
55. C Peters M Balthazor EG Shapiro RJ King C Kollman JD Hegland J Henslee-Downey ME Trigg MJ Cowan J Sanders N Bunin H Weinstein C Lenarsky P Falk R Harris T Bowen TE Williams GH Grayson P Warkentin L Sender VA Cool M Crittenden S Packman P Kaplan LA Lockman J Anderson W Krivit K Dusenbery J Wagner 1996 Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome Blood 87 4894 4902 1:CAS:528:DyaK28Xjt1Cksbs%3D 8639864
56. C Peters EG Shapiro W Krivit 1998 Neuropsychological development in children with Hurler syndrome following hematopoietic stem cell transplantation Pediatr Transplant 2 250 253 1:STN:280:DyaK1M7ot1ansg%3D%3D 10084724
57. TM Pierson CG Bonnemann RS Finkel N Bunin GI Tennekoon 2008 Umbilical cord blood transplantation for juvenile metachromatic leukodystrophy Ann Neurol 64 583 587 10.1002/ana.21522 19067349
58. FM Platt M Jeyakumar 2008 Substrate reduction therapy Acta Paediatr Suppl 97 88 93 10.1111/j.1651-2227.2008.00656.x 18339196
59. FM Platt GR Neises G Reinkensmeier MJ Townsend VH Perry RL Proia B Winchester RA Dwek TD Butters 1997 Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin Science 276 428 431 10.1126/science.276.5311.428 1:CAS:528:DyaK2sXis1Knsrk%3D 9103204
60. VK Prasad J Kurtzberg 2008 Emerging trends in transplantation of inherited metabolic diseases Bone Marrow Transplant 41 99 108 10.1038/sj.bmt.1705970 1:STN:280:DC%2BD1c%2Fnt1Oksw%3D%3D 18176609
61. MA Rafi H Zhi Rao MA Passini M Curtis MT Vanier M Zaka P Luzi JH Wolfe DA Wenger 2005 AAV-mediated expression of galactocerebrosidase in brain results in attenuated symptoms and extended life span in murine models of globoid cell leukodystrophy Mol Ther 11 734 744 10.1016/j.ymthe.2004.12.020 1:CAS:528:DC%2BD2MXjsFGqsbg%3D 15851012
62. M Ries JT Clarke C Whybra M Timmons C Robinson BL Schlaggar G Pastores YH Lien C Kampmann RO Brady M Beck R Schiffmann 2006 Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease Pediatrics 118 924 932 10.1542/peds.2005-2895 16950982
63. MS Sands ME Haskins 2008 CNS-directed gene therapy for lysosomal storage diseases Acta Paediatr Suppl 97 22 27 10.1111/j.1651-2227.2008.00660.x 18339183
64. R Sano A Tessitore A Ingrassia A d'Azzo 2005 Chemokine-induced recruitment of genetically modified bone marrow cells into the CNS of GM1-gangliosidosis mice corrects neuronal pathology Blood 106 2259 2268 10.1182/blood-2005-03-1189 1:CAS:528:DC%2BD2MXhtVKqt77E 15941905
65. PS Savas KM Hemsley JJ Hopwood 2004 Intracerebral injection of sulfamidase delays neuropathology in murine MPS-IIIA Mol Genet Metab 82 273 285 10.1016/j.ymgme.2004.05.005 1:CAS:528:DC%2BD2cXmslOgtLY%3D 15308125
66. R Schiffmann 2009 Fabry disease Pharmacol Ther 122 65 77 10.1016/j.pharmthera.2009.01.003 1:CAS:528:DC%2BD1MXkt1Sisr8%3D 19318041
67. R Schiffmann MP Heyes JM Aerts JM Dambrosia MC Patterson T DeGraba CC Parker GC Zirzow K Oliver G Tedeschi RO Brady NW Barton 1997 Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease Ann Neurol 42 613 621 10.1002/ana.410420412 1:CAS:528:DyaK2sXntVCks7w%3D 9382473
68. R Schiffmann MK Floeter JM Dambrosia S Gupta DF Moore Y Sharabi RK Khurana RO Brady 2003 Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease Muscle Nerve 28 703 710 10.1002/mus.10497 1:CAS:528:DC%2BD2cXht1Cjuw%3D%3D 14639584
69. R Schiffmann M Ries M Timmons JT Flaherty RO Brady 2006 Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting Nephrol Dial Transplant 21 345 354 10.1093/ndt/gfi152 1:CAS:528:DC%2BD28Xmsl2isw%3D%3D 16204287
70. R Schiffmann EJ Fitzgibbon C Harris C DeVile EH Davies L Abel IN van Schaik W Benko M Timmons M Ries A Vellodi 2008 Randomized, controlled trial of miglustat in Gaucher's disease type 3 Ann Neurol 64 514 522 10.1002/ana.21491 19067373
71. I Schrijver M Kulm PI Gardner EP Pergament MB Fiddler 2007 Comprehensive arrayed primer extension array for the detection of 59 sequence variants in 15 conditions prevalent among the (Ashkenazi) Jewish population J Mol Diagnostics 9 228 236 10.2353/jmoldx.2007.060100 1:CAS:528:DC%2BD2sXlt12ru7k%3D
72. Smith D, Wallom KL, Williams IM, Jeyakumar M, Platt FM (2009) Beneficial effects of anti-inflammatory therapy in a mouse model of Niemann-Pick disease type C1. Neurobiol Dis 36:242-251
73. M Sobrado MP Pereira I Ballesteros O Hurtado D Fernandez-Lopez JM Pradillo JR Caso J Vivancos F Nombela J Serena I Lizasoain MA Moro 2009 Synthesis of lipoxin A4 by 5-lipoxygenase mediates PPARgamma-dependent, neuroprotective effects of rosiglitazone in experimental stroke J Neurosci 29 3875 3884 10.1523/JNEUROSCI.5529-08.2009 1:CAS:528:DC%2BD1MXktVSqtbo%3D 19321784
74. BJ Spencer IM Verma 2007 Targeted delivery of proteins across the blood-brain barrier Proc Natl Acad Sci U S A 104 7594 7599 10.1073/pnas. 0702170104 1:CAS:528:DC%2BD2sXlslWqtLk%3D 17463083
75. Y Suzuki 2008 Chemical chaperone therapy for GM1-gangliosidosis Cell Mol Life Sci 65 351 353 10.1007/s00018-008-7470-2 1:CAS:528:DC%2BD1cXisFSltL4%3D 18202827
76. Tansey MG, Goldberg MS (2009) Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis (in press)
77. J Tolar SS Grewal KJ Bjoraker CB Whitley EG Shapiro L Charnas PJ Orchard 2008 Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for Hurler syndrome Bone Marrow Transplant 41 531 535 10.1038/sj.bmt.1705934 1:CAS:528:DC%2BD1cXjs12gsb8%3D 18037941
78. R Wada CJ Tifft RL Proia 2000 Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation Proc Natl Acad Sci U S A 97 10954 10959 10.1073/pnas.97.20.10954 1:CAS:528:DC%2BD3cXnt1ahsb4%3D 11005868
79. WR Wilcox M Banikazemi N Guffon S Waldek P Lee GE Linthorst RJ Desnick DP Germain 2004 Long-term safety and efficacy of enzyme replacement therapy for Fabry disease Am J Hum Genet 75 65 74 10.1086/422366 1:CAS:528: DC%2BD2cXltFClsrc%3D 15154115
80. S Worgall D Sondhi NR Hackett B Kosofsky MV Kekatpure N Neyzi JP Dyke D Ballon L Heier BM Greenwald P Christos M Mazumdar MM Souweidane MG Kaplitt RG Crystal 2008 Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA Hum Gene Ther 19 463 474 10.1089/hum.2008.022 1:CAS:528:DC%2BD1cXmsVGlsrg%3D 18473686
81. M Zervas KL Somers MA Thrall SU Walkley 2001 Critical role for glycosphingolipids in Niemann-Pick disease type C Curr Biol 11 1283 1287 10.1016/S0960-9822(01)00396-7 1:CAS:528:DC%2BD3MXmsFers7o%3D 11525744